Latest News
  1. Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
  2. Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
  3. KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment

News

First use of Dantrolene to save a malignant hyperthermia patient

First use of Dantrolene to save a malignant hyperthermia patient
News

Dantrolene was used for the first time to treat malignant hyperthermia, according to the Russian Federation of Anesthesiologists and Resuscitators. Employees of the Moscow State Medical University's Clinical Center of Maxillofacial Plastic Surgery and Dentistry named after A.I. Evdokimov rescued a patient who developed malignant hyperthermia (MH) after using an inhalation anaesthetic. The doctors used Dantrolene, which was approved in Russia a year ago, to stop the reaction. The reaction occurred an hour after the inhalational anaesthetic sevoflurane was administered to a 19-year-old patient undergoing orthognathic surgery. After ruling out all other possibilities, the doctors began treatment with Dantrolene injections.

The patient was discharged after a few days in the hospital after the episode was successfully stopped with 24 vials (480 mg) of Dantrolene. According to doctors, if the clinic did not have enough of the drug, the outcome would almost certainly be fatal, as the mortality rate for MH is 80%. It should be noted that the patient had no contraindications or features that could have affected the outcome of anaesthesia during the preoperative period.

Dantrolene production will begin in June 2022 at the OncoTarget manufacturing facility in Moscow. The drug is specifically designed to treat MH, an acute life-threatening condition in genetically predisposed individuals characterised by impaired calcium metabolism. MH is a side effect that can occur with the use of inhaled anaesthetics. This condition can lead to a series of complications, including multiple organ failure and a high mortality rate. MH is a side effect that can occur with the use of inhaled anaesthetics.